New York-based BMS will hold worldwide rights to whatever products emerge from the alliance...Its other partners include New York-based Pfizer Inc

GlycoMimetics partnered GMI-1070, a synthetic glycomimetic molecule designed to inhibit all three selectin types, in a worldwide agreement with Pfizer Inc., of New York, in 2011. (See BioWorld Today, Oct. 12, 2011

Almirall SA, of Barcelona, Spain, and Forest Laboratories Inc., of New York, reported top-line results from a six-month pivotal Phase III study testing fixed-dose combinations of aclidinium bromide, a long-acting muscarinic beta2 agonist, and formoterol fumarate, a long-acting beta2 agonist, delivered using Almirall's inhaler Genuair

M&A strategies in our business are hit and miss," said Eric Schmidt, managing director and senior research analyst at Cowen & Co., in New York

New York-based BMS will hold worldwide rights to whatever products emerge from the alliance...Its other partners include New York-based Pfizer Inc

Merck KGgA, of Darmstadt, Germany, reported that a collaboration agreement between its subsidiary, EMD Serono Inc., and Pfizer Inc., of New York, inked in July 2002 for the co-promotion of multiple sclerosis drug Rebif (interferon beta-1a) extends until Dec. 31, 2015, according to an appellate court ruling

The three-way arrangement with Pfizer and BMS, both of New York, to test a candidate that could reverse the anticoagulant effects of Factor Xa inhibitors may help all three firms eventually, but Portola was paid first

The three-way arrangement with Pfizer and BMS, both of New York, to test a candidate that could reverse the anticoagulant effects of Factor Xa inhibitors may help all three firms eventually, but Portola was paid first

Merck KGgA, of Darmstadt, Germany, reported that a collaboration agreement between its subsidiary, EMD Serono Inc., and Pfizer Inc., of New York, inked in July 2002 for the co-promotion of multiple sclerosis drug Rebif (interferon beta-1a) extends until Dec. 31, 2015, according to an appellate court ruling

M&A strategies in our business are hit and miss," said Eric Schmidt, managing director and senior research analyst at Cowen & Co., in New York

Kythera Biopharmaceuticals Inc., of New York, reported that MRI measurements of patients treated with ATX-101 demonstrated a statistically significant reduction in submental fat (SMF), commonly known as double chin, during an oral session at the Aesthetic Meeting 2013 in New York

Bristol-Myers Squibb Co., of New York, named Francis Cuss executive vice president and chief scientific officer, effective July 1

a steroid nucleus-based mineralocorticoid receptor antagonist Myocardial infarction The trial showed a 42.9% relative risk reduction in the primary endpoint 3/12/13 Pfizer Inc. (New York) Prevnar 13 Pneumococcal 13-valent conjugate vaccine HIV Phase III data demonstrated immunogenicity, tolerability and safety 3/6/13 Pfizer Inc. (New York) Xeljanz Tofacitinib citrate Rheumatoid arthritis Japanese regulators approved it 3/27/13 Phosphagenics Ltd. (Melbourne, Australia) Oxymorphone Patch Pain

New York) Uplyso Alfataliglicerase Gaucher disease Received regulatory approval in Brazil 3/19/13 Prothena Corp

New York) OHR/AVR118 Anti-inflammatory drug Advanced cancer with cachexia Phase II trial did not meet the primary endpoint of weight gain, but the 18 patients who completed treatment achieved stable body weight, body fat and muscle mass with a significant increase in appetite 3/22/13 Oncolytics Biotech Inc. (Calgary, Alberta) Reolysin Intravenous therapy Non-small-cell lung cancer...New York) Ad-RTS IL-12 Previously ZIN ATI-001 Nonresectable recurrent or metastatic breast cancer Started a Phase II

Bristol-Myers Squibb Co., of New York, will invest $250 million to expand its large-scale biologics manufacturing facility in Devens, Mass., introducing biologics development and clinical trial manufacturing capabilities and adding about 350 employees

New York) Palifosfamide Alkylating agent Metastatic soft tissue sarcoma Failed to meet the primary endpoint of progression-free survival 3/27/13 CARDIOVASCULAR Acasti Pharma Inc. (Laval, Quebec) NKPL66 CaPre Mild-to-high hypertriglyceridemia Preliminary data showed it achieved a statistically significant triglyceride reduction of up to 23%, compared to standard of care, after four weeks of treatment 3/20/13 Biogen Idec Inc. (Cambridge, Mass.) rRIXFc Recombinant factor IX Fc fusion protein

the drug also met a key secondary endpoint 3/22/13 Biotie Therapies Corp. (Turku, Finland) SYN115 Tozadenant Parkinson's disease Phase IIb data showed significant reductions in mean placebo-corrected change from baseline in "off" time were observed with tozadenant 120 mg BID and 180 mg BID 3/22/13 BrainStorm Cell Therapeutics Inc. (New York) NurOwn Technology for the propagation and differentiation of autologous mesenchymal stem cells into nuerotrophic factor-secreting cells Amyotrophic lateral

A partnership between Roche AG and Chiasma Inc., of New York, could generate a total of $595 million